Aliases & Classifications for Enthesopathy

MalaCards integrated aliases for Enthesopathy:

Name: Enthesopathy 12 15 73
Rheumatic Diseases 44
Rheumatism 73

Classifications:



External Ids:

Disease Ontology 12 DOID:204
ICD10 33 M77.9 M76.9
ICD9CM 35 726.9 726.90
MeSH 44 D012216

Summaries for Enthesopathy

MalaCards based summary : Enthesopathy, also known as rheumatic diseases, is related to tendinitis and hypophosphatemic rickets, x-linked dominant, and has symptoms including musculoskeletal symptom, myalgia and joint symptom. An important gene associated with Enthesopathy is PHEX (Phosphate Regulating Endopeptidase Homolog X-Linked). The drugs Methotrexate and Hydroxychloroquine have been mentioned in the context of this disorder. Affiliated tissues include bone, testes and heart, and related phenotype is growth/size/body region.

Wikipedia : 76 In medicine, an enthesopathy refers to a disorder involving the attachment of a tendon or ligament to a... more...

Related Diseases for Enthesopathy

Diseases related to Enthesopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 79)
# Related Disease Score Top Affiliating Genes
1 tendinitis 30.3 MRAP PHB2
2 hypophosphatemic rickets, x-linked dominant 29.9 DMP1 FGF23 PHEX
3 hypophosphatemia 29.9 DMP1 FGF23 PHEX
4 bursitis 29.8 MRAP PHB2
5 diffuse idiopathic skeletal hyperostosis 11.3
6 epicondylitis 10.5
7 opsismodysplasia 10.5 FGF23 PHEX
8 familial tumoral calcinosis 10.4 FGF23 PHEX
9 hypophosphatemic rickets, autosomal dominant 10.4 FGF23 PHEX
10 arterial calcification of infancy 10.4 FGF23 PHEX
11 raine syndrome 10.3 DMP1 FGF23
12 iris disease 10.3 MRAP PHEX
13 mineral metabolism disease 10.3 FGF23 PHEX
14 arthritis 10.2
15 hyperphosphatemia 10.2 FGF23 PHEX
16 balanitis 10.2 MRAP PHB2
17 psoriasis 10.2
18 iritis 10.2 MRAP PHB2
19 arthropathy 10.2
20 bone remodeling disease 10.2 FGF23 PHEX
21 byssinosis 10.2 MEFV MRAP
22 urethritis 10.1 MRAP PHB2
23 spondyloarthropathy 1 10.1
24 spondylitis 10.1
25 penile disease 10.1 MRAP PHB2
26 palindromic rheumatism 10.1 MEFV MRAP
27 psoriatic arthritis 10.1
28 transient arthritis 10.1 MRAP PHB2
29 osteoarthritis 10.1
30 calcinosis 10.1 FGF23 PHEX
31 hyperostosis 10.1
32 urethral syndrome 10.0 MRAP PHB2
33 spondyloarthropathy 10.0
34 periarthritis 10.0
35 familial mediterranean fever 10.0
36 tendinopathy 10.0
37 brucellosis 10.0
38 oncogenic osteomalacia 9.9 DMP1 FGF23 PHEX
39 autosomal recessive hypophosphatemic rickets 9.9 DMP1 FGF23 PHEX
40 phosphorus metabolism disease 9.9 DMP1 FGF23 PHEX
41 hypophosphatemic rickets, x-linked recessive 9.9 DMP1 FGF23 PHEX
42 hypophosphatemic rickets with hypercalciuria, hereditary 9.9 DMP1 FGF23 PHEX
43 osteomalacia 9.9 DMP1 FGF23 PHEX
44 rickets 9.9 DMP1 FGF23 PHEX
45 patellar tendinitis 9.9
46 achilles bursitis 9.9
47 heel spur 9.9
48 aging 9.8
49 rheumatic disease 9.8
50 synovitis 9.8

Comorbidity relations with Enthesopathy via Phenotypic Disease Network (PDN):


Acute Cystitis Hypertension, Essential

Graphical network of the top 20 diseases related to Enthesopathy:



Diseases related to Enthesopathy

Symptoms & Phenotypes for Enthesopathy

UMLS symptoms related to Enthesopathy:


musculoskeletal symptom, myalgia, joint symptom

MGI Mouse Phenotypes related to Enthesopathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.1 DMP1 FGF23 MEFV PHB2 PHEX SERPINI2

Drugs & Therapeutics for Enthesopathy

Drugs for Enthesopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 934)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
2
Hydroxychloroquine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 118-42-3 3652
3
Infliximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 170277-31-3
4
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 83-43-2 6741
5
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 16590-41-3 5360515
6
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-24-8 5755
7
Sulfasalazine Approved Phase 4,Phase 3,Phase 2,Not Applicable 599-79-1 5353980 5359476
8
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 185243-69-0
9
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2216-51-5 16666
10
Leflunomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 75706-12-6 3899
11
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 124-94-7 31307
12
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
13
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 103-90-2 1983
14
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 9004-61-9 53477741
15
Iron Approved Phase 4,Phase 3,Phase 1,Phase 2 7439-89-6 23925
16
Rivaroxaban Approved Phase 4,Phase 3,Not Applicable 366789-02-8
17
Tranexamic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1197-18-8 5526
18
Tranylcypromine Approved, Investigational Phase 4 155-09-9 441233
19
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 169590-42-5 2662
20
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 161796-78-7, 119141-88-7 4594 9579578
21
Naproxen Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22204-53-1 1302 156391
22
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 2180-92-9, 38396-39-3 2474
23
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
24
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
25
Ropivacaine Approved Phase 4,Phase 3,Phase 2,Not Applicable 84057-95-4 71273 175805
26
Cimetidine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 51481-61-9 2756
27
Hyoscyamine Approved Phase 4 101-31-5 64692
28
Milnacipran Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 92623-85-3 65833
29
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-41-2 439260
30
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
31
Etoricoxib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 202409-33-4 123619
32
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 331731-18-1 16219006
33
Fluorouracil Approved Phase 4 51-21-8 3385
34
Tacrolimus Approved, Investigational Phase 4,Phase 3,Early Phase 1 104987-11-3 445643 439492
35
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 15307-86-5 3033
36
Abatacept Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 332348-12-6 10237
37
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
38
Amitriptyline Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-48-6 2160
39
Cyclobenzaprine Approved Phase 4,Phase 3,Phase 2,Not Applicable 303-53-7 2895
40
Certolizumab pegol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 428863-50-7
41
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-43-4 5816
42
Ketorolac Approved Phase 4,Phase 3,Phase 2,Not Applicable 74103-06-3, 66635-83-4 3826
43
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 57-27-2 5288826
44
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 329-65-7 838
45
Calcium Carbonate Approved, Investigational Phase 4,Phase 3,Phase 2 471-34-1
46
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
47
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
48
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
49
Betamethasone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 378-44-9 9782
50
Aminocaproic Acid Approved, Investigational Phase 4,Phase 2,Not Applicable 60-32-2 564

Interventional clinical trials:

(show top 50) (show all 6282)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
2 Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis Unknown status NCT02087696 Phase 4 Tocilizumab
3 Vaccination Against Pertussis, Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
4 TNF-blocking Therapy in Combination With Disease-modifying Antirheumatic Drugs in Early Rheumatoid Arthritis Unknown status NCT00908089 Phase 4 Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab;Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo
5 Very Early Versus Delayed Etanercept in Patients With RA Unknown status NCT02433184 Phase 4 Etanercept;Methotrexate;Sulfasalazine;Hydroxychloroquine;Etanercept;Methotrexate
6 Remission Induction in Very Early Rheumatoid Arthritis Unknown status NCT00523692 Phase 4 Etanercept, methotrexate and depomedrone;depemedrone
7 Efficacy Study of Leflunomide to Treat Juvenile Idiopathic Arthritis Unknown status NCT02024334 Phase 4 Leflunomide
8 Targeting Synovitis in Early Rheumatoid Arthritis Unknown status NCT00920478 Phase 4
9 Obesity Cohort : Medical Follow-up of Severe or Morbid Obese Patients Undergoing Bariatric Surgery Unknown status NCT02310178 Phase 4
10 Influence of Perception of Patients Suffering of Knee Osteoarthritis Regarding Effectiveness of Intra-articular Injection Unknown status NCT02835521 Phase 4 Joint injection with triamcinolone hexacetonide
11 Safety and Efficacy of Intra-articular Ozone Injections for Knee Osteoarthritis Unknown status NCT02833545 Phase 4
12 Intra-articular Botox Type A Versus Corticosteroids in Knee Osteoarthritis Unknown status NCT02829281 Phase 4 Botulinum Toxin Type A;Triamcinolone hexacetonide;Saline
13 Evaluation of the Evolution of Imaging Markers of Cartilage Degradation in Patients With Knee Osteoarthritis Receiving DROGLICAN Unknown status NCT02821468 Phase 4 Droglican;Paracetamol or oral NSAIDs excluding COX2 inhibitors
14 Assessment of a Knee Brace in Patients With Osteoarthritis Unknown status NCT02706106 Phase 4
15 Effectiveness of Trapeziometacarpal Splint Unknown status NCT02635932 Phase 4
16 Effects of Hyaluronic Acid vs. Hyaluronic Acid on Knee Osteoarthritis Unknown status NCT02625727 Phase 4
17 Intravenous Iron Sucrose in Arthroplasty Unknown status NCT02544828 Phase 4 Iron Sucrose 200mg;placebo
18 Does Intraoperative Intravenous Iron Enhance Postoperative Oxygenation Profile in Total Knee Arthroplasty Surgery? Unknown status NCT02544464 Phase 4 ferric carboxymaltose 1000 mg;placebo
19 The Post-marketing Surveillance to Evaluate the Efficacy of CHONDRON (Autologous Cultured Chondrocyte) by Arthroscopy Unknown status NCT02539069 Phase 4
20 The Post-marketing Surveillance to Evaluate the Efficacy and Safety of a CHONDRON (Autologous Cultured Chondrocyte) Unknown status NCT02539056 Phase 4
21 Multi-center Clinical Study of Guli Capsules in the Treatment of Knee Osteoarthritis Unknown status NCT02484508 Phase 4 Guli capsule;Kangguzengsheng capsule
22 Comparison of Topical and Infusion Tranexamic Acid After Total Knee Arthroplasty Unknown status NCT02453802 Phase 4 Tranexamic Acid 5%,5ml/amp;Tranexamic Acid 5%,5ml/amp;rivaroxaban (10mg);0.9% Normal Saline;0.9% Normal Saline
23 Validation of a Stress Device for the Knee Unknown status NCT02444663 Phase 4
24 Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis Unknown status NCT02355236 Phase 4 Naproxen/Esomeprazol 500/20mg;Celecoxib 200mg;Naxozol-Placebo;Comparator-Placebo
25 Medical Chitosan or Sodium Hyaluronate for Knee Osteoarthritis (CHOOSE) Unknown status NCT02323451 Phase 4 Sodium Hyaluronate Injection
26 Tranexamic Acid in Knee Joint Surgery Unknown status NCT02278263 Phase 4 Tranexamic Acid;Normal saline (0.9% NaCl)
27 Comparison of Floseal® and Tranexamic Acid on Bleeding Control After Total Knee Arthroplasty Unknown status NCT02152917 Phase 4 Tranexamic acid;Floseal®
28 Intraarticular Xylitol Injections for Knee Osteoarthritis Unknown status NCT02104596 Phase 4
29 Daily Activity and Gait Analysis After Viscosupplement Injection Among Hip Osteoarthritis Patients Unknown status NCT02086474 Phase 4 Hyaluronan;Bupivacaine
30 The Effect of Spironolactone on Pain in Older People With Osteoarthritis Unknown status NCT02046668 Phase 4 spironolactone
31 Outcome Comparison of Allograft and Synthetic Bone Substitute in High Tibial Osteotomy Unknown status NCT02000297 Phase 4
32 A Phase 4 Study of Imrecoxib in Treatment of Knee Osteoarthritis Unknown status NCT01985165 Phase 4 Imrecoxib
33 Comparison of Femoral Nerve Catheter and Adductor Canal Block With Steroid Adjuvant in Total Knee Replacement (TKR) Unknown status NCT01973530 Phase 4
34 Reinflation After Early Tourniquet Release in Total Knee Arthroplasty Unknown status NCT01832272 Phase 4
35 Hip Viscosupplementation: What is the Best Dosage? Unknown status NCT01810809 Phase 4 1 ampoule of Hylan GF-20;2 ampoules of Hylan GF-20;3 ampoules of Hylan GF-20
36 Bone Forming at Prosthetic Surfaces. Fingerprint2 Unknown status NCT01623687 Phase 4
37 RSA Study Using Two Types of Uncemented Acetabular Components and the Uncemented HA Coated Symax Stem Unknown status NCT01618084 Phase 4
38 Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis Unknown status NCT01329406 Phase 4 Milnacipran;Placebo
39 Chondroitin Sulphate Treatment Efficacy in Rhizarthrosis. Unknown status NCT01233739 Phase 4 Chondroitin sulfate;Placebo
40 Assessment of the Effects of Chondroitin Sulphate in Patients With Knee Osteoarthritis With Functional Magnetic Resonance Imaging (fMRI) Unknown status NCT01226615 Phase 4 Chondroitin sulphate (Condrosan®);Placebo
41 Prophecy Guide Outcomes in Total Knee Replacement Surgery Unknown status NCT01163708 Phase 4
42 Comparison of Outcomes in Mobile and Fixed-bearing Total Knee Arthroplasty Unknown status NCT01027819 Phase 4
43 The Impact of Hyaluronic Acid Injections on Osteoarthritic Knee Mechanics Unknown status NCT00778076 Phase 4
44 Use of Cold and Compression Therapy With Total Knee Replacement Patients Unknown status NCT00712816 Phase 4
45 Trial Comparing Navigated and Conventional Implantation Techniques in Knee Replacement Surgery Unknown status NCT00431509 Phase 4
46 The Effect of Intraaricular Knee Injections of Hyaluronic Acid (HA) on Bone and Cartilaginous Debris, as a Therapeutic Indicator Unknown status NCT00422643 Phase 4 Sodium hyaluronate (hyaluronic acid)
47 Effectiveness Study of Hylan G-F 20 to Preserve Cartilage in Osteoarthritis of the Knee Unknown status NCT00393393 Phase 4 intra-articular injection of Hylan G-F 20
48 Effect of Flex-a-New on Osteoarthritis of the Knee Unknown status NCT00294801 Phase 4 flex-a-new (food supplement)
49 Comparing Clinical Outcome of 2 Different Total Knee Prostheses: Nexgen LPS-Flex Versus AGC Unknown status NCT00294528 Phase 4
50 Efficacy of Celecoxib Vs Placebo to Prevent Pain in a Paced Walk Unknown status NCT00194090 Phase 4 celecoxib

Search NIH Clinical Center for Enthesopathy

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: rheumatic diseases

Genetic Tests for Enthesopathy

Anatomical Context for Enthesopathy

MalaCards organs/tissues related to Enthesopathy:

41
Bone, Testes, Heart, Eye, Bone Marrow, Brain, Skin

Publications for Enthesopathy

Articles related to Enthesopathy:

(show top 50) (show all 1106)
# Title Authors Year
1
Approach to Patients with Suspected Rheumatic Disease. ( 29759118 )
2018
2
Development of neoplasms in pediatric patients with rheumatic disease exposed to anti-tumor necrosis factor therapies: a single Centre retrospective study. ( 29540190 )
2018
3
Confidence amongst Multidisciplinary Professionals in Managing Paediatric Rheumatic Disease in Australia. ( 29593902 )
2018
4
Retinal Vessel Diameters and Physical Activity in Patients With Mild to Moderate Rheumatic Disease Without Cardiovascular Comorbidities. ( 29593551 )
2018
5
Prescribing for Children with Rheumatic Disease: Perceived Treatment Approaches between Pediatric and Adult Rheumatologists. ( 29481725 )
2018
6
Psoriasis and the risk of foot and ankle tendinopathy or enthesopathy in the absence of psoriatic arthritis: a population-based study. ( 29862046 )
2018
7
Can we prescribe TMP/SMX prophylaxis without any concerns equally for all patients with rheumatic disease? ( 29437584 )
2018
8
Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience. ( 29363290 )
2018
9
Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial. ( 29904824 )
2018
10
Prevalence of anti-DFS70 antibodies in patients with and without systemic autoimmune rheumatic diseases. ( 28770702 )
2018
11
Rapid glucocorticoid tapering therapy to reduce mortality from pneumocystis pneumonia in patients with rheumatic disease. ( 29972334 )
2018
12
Correction to: Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event. ( 29637430 )
2018
13
The Brave New World of Rheumatic Disease Research Today. ( 29622303 )
2018
14
Biosimilars: An opportunity. Position statement of the French Rheumatology Society (SFR) and Inflammatory Rheumatic Disease Club (CRI). ( 29574143 )
2018
15
Effectiveness and Drug Survival of Anti-Tumor Necrosis Factor I+ Therapies in Patients With Spondyloarthritis: Analysis From the Thai Rheumatic Disease Prior Authorization Registry. ( 29517554 )
2018
16
Asymptomatic Rhabdomyolysis and Digital Necrosis-Clues for a Rheumatic Disease. ( 29742540 )
2018
17
Response to: 'Can we prescribe TMP/SMX prophylaxis without any concerns equally for all patients with rheumatic disease?' by Suyama and Okada. ( 29437583 )
2018
18
Rheumatic Disease: Protease-Activated Receptor-2 in Synovial Joint Pathobiology. ( 29875735 )
2018
19
Endothelial progenitor cells and rheumatic disease modifying therapy. ( 29842927 )
2018
20
Aberrant TGF-I^ activation in bone tendon insertion induces enthesopathy-like disease. ( 29355842 )
2018
21
Rheumatic Disease Autoantibodies in Patients with Autoimmune Thyroid Diseases. ( 29864750 )
2018
22
The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review. ( 29318514 )
2018
23
Identification of new biomarkers to promote personalised treatment of patients with inflammatory rheumatic disease: protocol for an open cohort study. ( 29391382 )
2018
24
Predictors for influenza vaccine acceptance among patients with inflammatory rheumatic diseases. ( 29980390 )
2018
25
Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors. ( 29667098 )
2018
26
Rice-body formation without rheumatic disease or tuberculosis in a "sausage" ring finger. ( 29786532 )
2018
27
Subclinical enthesopathy of extensor digitorum tendon is highly prevalent and associated with clinical and ultrasound alterations of the adjacent fingernails in patients with psoriatic disease. ( 29706002 )
2018
28
Translating GWAS in rheumatic disease: approaches to establishing mechanism and function for genetic associations with ankylosing spondylitis. ( 29741584 )
2018
29
Determination of Specificity and Pattern of Antinuclear Antibodies (ANA) in Systemic Rheumatic Disease Patients Positive for ANA Testing. ( 29290190 )
2018
30
The rheumatic disease-associated FAM167A-BLK locus encodes DIORA-1, a novel disordered protein expressed highly in bronchial epithelium and alveolar macrophages. ( 29663334 )
2018
31
Sexual and reproductive health in rheumatic disease. ( 28680137 )
2017
32
Filling the gaps in SARDs research: collection and linkage of administrative health data and self-reported survey data for a general population-based cohort of individuals with and without diagnoses of systemic autoimmune rheumatic disease (SARDs) from British Columbia, Canada. ( 28637725 )
2017
33
Enthesopathy in rheumatoid arthritis and spondyloarthritis: An ultrasound study. ( 29233691 )
2017
34
Systematic review and meta-analysis of the epidemiology of polyautoimmunity in SjAPgren's syndrome (secondary SjAPgren's syndrome) focusing on autoimmune rheumatic diseases. ( 28927315 )
2017
35
Clinical characteristics of autoimmune rheumatic disease-related organizing pneumonia. ( 28748510 )
2017
36
Re: Did King Herod suffer from a rheumatic disease? doi: 10.1007/s10067-017-3583-z. ( 28733792 )
2017
37
Ehlers-Danlos syndrome hypermobility type is associated with rheumatic diseases. ( 28051109 )
2017
38
Macrophage Activation Syndrome in Paediatric Rheumatic Diseases. ( 28588173 )
2017
39
Paediatric rheumatic disease: Systemic JIA genetically distinct. ( 28077866 )
2017
40
Simple screening tools predict death and cardiovascular events in patients with rheumatic disease. ( 28812405 )
2017
41
Adaptation to inflammatory rheumatic disease: Do illness representations predict patients' physical functioning over time? A complex relationship. ( 28936564 )
2017
42
The endocannabinoid system in pain and inflammation: Its relevance to rheumatic disease. ( 29164003 )
2017
43
Plantar fascia enthesopathy is highly prevalent in diabetic patients without peripheral neuropathy and correlates with retinopathy and impaired kidney function. ( 28358891 )
2017
44
Mortality causes and outcomes in Indigenous populations of Canada, the United States, and Australia with rheumatic disease: A systematic review. ( 28823732 )
2017
45
Intratissue percutaneous electolysis combined with active physical therapy for the treatment of adductor longus enthesopathy-related groin pain: a randomized trial. ( 28116876 )
2017
46
Biologic Agents in the Treatment of Childhood-Onset Rheumatic Disease. ( 28711176 )
2017
47
Post-Chikungunya Rheumatic Disease in a 13-Year-Old Boy. ( 28884916 )
2017
48
Ultrasonographic Enthesopathy and Disease Activity in Psoriatic Arthritis. ( 28932308 )
2017
49
Clinical and ultrasonographic enthesopathy in inflammatory rheumatic diseases : Is MASEI or only calcaneal enthesitis sufficient? ( 29116386 )
2017
50
Paediatric rheumatic disease: What is the best definition of clinical remission in JIA? ( 28725036 )
2017

Variations for Enthesopathy

Expression for Enthesopathy

Search GEO for disease gene expression data for Enthesopathy.

Pathways for Enthesopathy

GO Terms for Enthesopathy

Biological processes related to Enthesopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 biomineral tissue development GO:0031214 9.26 DMP1 PHEX
2 cellular response to vitamin D GO:0071305 9.16 FGF23 PHEX
3 cellular response to parathyroid hormone stimulus GO:0071374 8.96 FGF23 PHEX
4 response to sodium phosphate GO:1904383 8.62 FGF23 PHEX

Sources for Enthesopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....